Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

A model for RAS mutation patterns in cancers: finding the sweet spot.

Li S, Balmain A, Counter CM.

Nat Rev Cancer. 2018 Dec;18(12):767-777. doi: 10.1038/s41568-018-0076-6. Review.

PMID:
30420765
2.

Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.

Adhikari H, Counter CM.

Nat Commun. 2018 Sep 7;9(1):3646. doi: 10.1038/s41467-018-05692-6.

3.

Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.

Xu M, Casio M, Range DE, Sosa JA, Counter CM.

Clin Cancer Res. 2018 Sep 1;24(17):4271-4281. doi: 10.1158/1078-0432.CCR-17-3705. Epub 2018 Jul 31.

4.

Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells.

Kabiri Z, Greicius G, Zaribafzadeh H, Hemmerich A, Counter CM, Virshup DM.

J Clin Invest. 2018 Aug 31;128(9):3806-3812. doi: 10.1172/JCI99325. Epub 2018 Jul 30.

5.

Wild-type Kras expands and exhausts hematopoietic stem cells.

Sasine JP, Himburg HA, Termini CM, Roos M, Tran E, Zhao L, Kan J, Li M, Zhang Y, de Barros SC, Rao DS, Counter CM, Chute JP.

JCI Insight. 2018 Jun 7;3(11). pii: 98197. doi: 10.1172/jci.insight.98197. eCollection 2018 Jun 7.

6.

Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

Brady DC, Crowe MS, Greenberg DN, Counter CM.

Cancer Res. 2017 Nov 15;77(22):6240-6252. doi: 10.1158/0008-5472.CAN-16-1190. Epub 2017 Oct 6.

7.

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, Wood KC.

Cell Rep. 2017 Jul 25;20(4):999-1015. doi: 10.1016/j.celrep.2017.07.006.

8.

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.

Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A, Counter CM, Wood KC.

Nat Commun. 2017 Jun 8;8:15617. doi: 10.1038/ncomms15617.

9.

Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.

Weyandt JD, Carney JM, Pavlisko EN, Xu M, Counter CM.

PLoS One. 2016 Dec 2;11(12):e0167205. doi: 10.1371/journal.pone.0167205. eCollection 2016.

10.

Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.

Pershing NL, Yang CFJ, Xu M, Counter CM.

Oncotarget. 2016 Jul 5;7(27):42385-42392. doi: 10.18632/oncotarget.9874.

11.

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.

Weyandt JD, Lampson BL, Tang S, Mastrodomenico M, Cardona DM, Counter CM.

PLoS One. 2015 Oct 9;10(10):e0140253. doi: 10.1371/journal.pone.0140253. eCollection 2015.

12.

A Genetic Porcine Model of Cancer.

Schook LB, Collares TV, Hu W, Liang Y, Rodrigues FM, Rund LA, Schachtschneider KM, Seixas FK, Singh K, Wells KD, Walters EM, Prather RS, Counter CM.

PLoS One. 2015 Jul 1;10(7):e0128864. doi: 10.1371/journal.pone.0128864. eCollection 2015.

13.

Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.

Huang L, Counter CM.

PLoS One. 2015 Apr 22;10(4):e0123918. doi: 10.1371/journal.pone.0123918. eCollection 2015.

14.

Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.

Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, Counter CM, Kashatus DF.

Mol Cell. 2015 Feb 5;57(3):537-51. doi: 10.1016/j.molcel.2015.01.002.

15.

Rare codons capacitate Kras-driven de novo tumorigenesis.

Pershing NL, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, Counter CM.

J Clin Invest. 2015 Jan;125(1):222-33. doi: 10.1172/JCI77627. Epub 2014 Dec 1.

16.

Decreased tumorigenesis in mice with a Kras point mutation at C118.

Huang L, Carney J, Cardona DM, Counter CM.

Nat Commun. 2014 Nov 14;5:5410. doi: 10.1038/ncomms6410.

17.

Copper is required for oncogenic BRAF signalling and tumorigenesis.

Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM.

Nature. 2014 May 22;509(7501):492-6. doi: 10.1038/nature13180. Epub 2014 Apr 9.

18.

Cell cycle regulated phosphorylation of the telomere-associated protein TIN2.

Yang S, Counter CM.

PLoS One. 2013 Aug 16;8(8):e71697. doi: 10.1371/journal.pone.0071697. eCollection 2013.

19.

Rare codons regulate KRas oncogenesis.

Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM.

Curr Biol. 2013 Jan 7;23(1):70-5. doi: 10.1016/j.cub.2012.11.031. Epub 2012 Dec 13.

20.

Snm1B interacts with PSF2.

Stringer JR, Counter CM.

PLoS One. 2012;7(11):e49626. doi: 10.1371/journal.pone.0049626. Epub 2012 Nov 26.

21.

Targeting eNOS in pancreatic cancer.

Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, Counter CM.

Cancer Res. 2012 Sep 1;72(17):4472-82. doi: 10.1158/0008-5472.CAN-12-0057. Epub 2012 Jun 27.

22.

Breaking up is hard to do: RalA, mitochondrial fission and cancer.

Kashatus DF, Counter CM.

Small GTPases. 2011 Nov 1;2(6):329-333.

23.

PinX1 localizes to telomeres and stabilizes TRF1 at mitosis.

Yonekawa T, Yang S, Counter CM.

Mol Cell Biol. 2012 Apr;32(8):1387-95. doi: 10.1128/MCB.05641-11. Epub 2012 Feb 13.

24.

A novel role for copper in Ras/mitogen-activated protein kinase signaling.

Turski ML, Brady DC, Kim HJ, Kim BE, Nose Y, Counter CM, Winge DR, Thiele DJ.

Mol Cell Biol. 2012 Apr;32(7):1284-95. doi: 10.1128/MCB.05722-11. Epub 2012 Jan 30.

25.

RALA and RALBP1 regulate mitochondrial fission at mitosis.

Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM.

Nat Cell Biol. 2011 Aug 7;13(9):1108-15. doi: 10.1038/ncb2310.

26.

Ral activation promotes melanomagenesis.

Zipfel PA, Brady DC, Kashatus DF, Ancrile BD, Tyler DS, Counter CM.

Oncogene. 2010 Aug 26;29(34):4859-64. doi: 10.1038/onc.2010.224. Epub 2010 Jun 21.

27.

cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis.

Vignola MJ, Kashatus DF, Taylor GA, Counter CM, Valdivia RH.

J Biol Chem. 2010 Jul 9;285(28):21625-35. doi: 10.1074/jbc.M110.103010. Epub 2010 May 7.

28.

Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.

Issaq SH, Lim KH, Counter CM.

Mol Cancer Res. 2010 Feb;8(2):223-31. doi: 10.1158/1541-7786.MCR-09-0189. Epub 2010 Feb 9.

29.

Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM.

Mol Cell Biol. 2010 Jan;30(2):508-23. doi: 10.1128/MCB.00916-08. Epub 2009 Nov 9.

30.

Utility of telomerase-pot1 fusion protein in vascular tissue engineering.

Petersen TH, Hitchcock T, Muto A, Calle EA, Zhao L, Gong Z, Gui L, Dardik A, Bowles DE, Counter CM, Niklason LE.

Cell Transplant. 2010;19(1):79-87. doi: 10.3727/096368909X478650. Epub 2009 Oct 29.

31.

ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis.

O'Hayer KM, Brady DC, Counter CM.

Carcinogenesis. 2009 Nov;30(11):1841-7. doi: 10.1093/carcin/bgp198. Epub 2009 Oct 5.

32.

POT1 association with TRF2 regulates telomere length.

Kendellen MF, Barrientos KS, Counter CM.

Mol Cell Biol. 2009 Oct;29(20):5611-9. doi: 10.1128/MCB.00286-09. Epub 2009 Aug 3.

33.

Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.

Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM.

Cancer Res. 2008 Dec 1;68(23):9583-8. doi: 10.1158/0008-5472.CAN-07-6178.

34.

The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.

Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP.

Cancer Res. 2008 Sep 15;68(18):7561-9. doi: 10.1158/0008-5472.CAN-08-0188.

35.

Creating porcine biomedical models through recombineering.

Rogatcheva MM, Rund LA, Swanson KS, Marron BM, Beever JE, Counter CM, Schook LB.

Comp Funct Genomics. 2004;5(3):262-7. doi: 10.1002/cfg.404.

36.

The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2.

Freibaum BD, Counter CM.

J Biol Chem. 2008 Aug 29;283(35):23671-6. doi: 10.1074/jbc.M800388200. Epub 2008 Jul 1.

37.

Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells.

Tomlinson RL, Abreu EB, Ziegler T, Ly H, Counter CM, Terns RM, Terns MP.

Mol Biol Cell. 2008 Sep;19(9):3793-800. doi: 10.1091/mbc.E08-02-0184. Epub 2008 Jun 18.

38.

Distinct functions of POT1 at telomeres.

Barrientos KS, Kendellen MF, Freibaum BD, Armbruster BN, Etheridge KT, Counter CM.

Mol Cell Biol. 2008 Sep;28(17):5251-64. doi: 10.1128/MCB.00048-08. Epub 2008 Jun 2.

39.

Genetic modeling of Ras-induced human rhabdomyosarcoma.

Linardic CM, Counter CM.

Methods Enzymol. 2008;438:419-27. doi: 10.1016/S0076-6879(07)38028-2.

40.

A method to generate genetically defined tumors in pigs.

Adam SJ, Counter CM.

Methods Enzymol. 2008;439:39-51. doi: 10.1016/S0076-6879(07)00404-1.

41.

Tumour maintenance is mediated by eNOS.

Lim KH, Ancrile BB, Kashatus DF, Counter CM.

Nature. 2008 Apr 3;452(7187):646-9. doi: 10.1038/nature06778. Epub 2008 Mar 16.

42.

Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.

Ancrile BB, O'Hayer KM, Counter CM.

Mol Interv. 2008 Feb;8(1):22-7. doi: 10.1124/mi.8.1.6. Review.

43.

Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation.

Etheridge KT, Compton SA, Barrientos KS, Ozgur S, Griffith JD, Counter CM.

J Biol Chem. 2008 Mar 14;283(11):6935-41. doi: 10.1074/jbc.M708711200. Epub 2008 Jan 3.

44.

Characterization of the porcine ATM gene: towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia.

Rogatcheva MB, Fritz KL, Rund LA, Pollock CB, Beever JE, Counter CM, Schook LB.

Gene. 2007 Dec 15;405(1-2):27-35. Epub 2007 Aug 30.

PMID:
17933474
45.

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

Ancrile B, Lim KH, Counter CM.

Genes Dev. 2007 Jul 15;21(14):1714-9.

46.

The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM.

Cancer Res. 2007 Jul 15;67(14):6691-9.

47.

Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM.

Curr Biol. 2006 Dec 19;16(24):2385-94.

48.

Genetic induction of tumorigenesis in swine.

Adam SJ, Rund LA, Kuzmuk KN, Zachary JF, Schook LB, Counter CM.

Oncogene. 2007 Feb 15;26(7):1038-45. Epub 2006 Sep 11.

PMID:
16964292
49.

A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro.

O'Hayer KM, Counter CM.

Methods Enzymol. 2006;407:637-47. Review.

PMID:
16757358
50.

Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.

Baines AT, Lim KH, Shields JM, Lambert JM, Counter CM, Der CJ, Cox AD.

Methods Enzymol. 2006;407:556-74.

PMID:
16757353

Supplemental Content

Loading ...
Support Center